A Phase 3 interventional study of Infasurf Aero™ in Respiratory Distress Syndrome (Neonatal), Intubation Complication and Death; Neonatal, sponsored by ONY. Recruiting at 10 sites in United States. Open to participants aged 29 Weeks to 36 Weeks. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by ONY · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Pulmonary Atelectasis with a site in United States — 11 open to participants now, 11 under way, 1 of them phase 3. Pulmonary Atelectasis · United States.
Among the 43 studies in Pulmonary Atelectasis with a site in United States, this one is the 6th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 33rd registered.
378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.
Browse Pulmonary Atelectasis studies →11 of the 43 studies in Pulmonary Atelectasis with a site in United States are open now. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 0 hrs–72 hrs
University of Texas Southwestern Medical Center · Sites in United States
Ages 0 hrs–3 days
University of Arkansas · Sites in United States
Hackensack Meridian Health · Sites in United States
Ages 34 wk–36 wk
NYU Langone Health · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Pulmonary Atelectasis studies recruiting now, 20 (39%) set no upper age limit and 23 (45%) stop at 75 or younger; 24 take children under 18; 2 take healthy volunteers.
This study: 29 Weeks to 36 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2005; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 220 is above the median of 60 across 268 interventional studies indexed under Pulmonary Atelectasis.
Median enrollment 40 across the 37 interventional studies, 300 across the 5 observational. Of the 26 that completed or were terminated, 13 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 43 have an industry lead sponsor. The 10 most frequent:
ONY is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
ONY has 2 studies filed under Pulmonary Atelectasis — fewer than ten, so there is no comparison to draw.
5 of the studies in Pulmonary Atelectasis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT07674953University of ArkansasHow Different Levels of CPAP Affect Oxygen Delivery and Lung Expansion in Preterm Infants | 2026-12 |
| NCT05675345NYU Langone HealthPhysiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure | 2027-06-30 |
| NCT07418502University of Texas at AustinPressure Targeting During High Flow Therapy in Premature Infants | 2027-08 |
| NCT07216053Hackensack Meridian HealthPredictive Value of Lung Ultrasound for Respiratory Decompensation in Late Preterm Neonates | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Pulmonary Atelectasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.
This single-dose, double-blind, random allocation, sham-control, clinical trial will recruit spontaneously breathing newborns with RDS stable on non-invasive nasal respiratory support. Enrolled clinical study subjects will be randomly allocated to receive respiratory air with Infasurf® (Intervention Arm) or respiratory air alone (Sham Control Arm) through the InfasurfAero™.
The objectives of this clinical study are to i) assess the effectiveness of a single dose of Infasurf administered through the InfasurfAero in preventing CPAP failure, and ii) assess the safety of Infasurf administered through the InfasurfAero.
Subjects will be enrolled at one of 10+ sites. 7 sites are currently recruited.
Inclusion Criteria:
Inclusion criteria include ALL of the following:
Exclusion Criteria:
Exclusion criteria are ANY of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of Calfactant at 6ml/kg administered via the Infasurf Aero™ Nebulizer until completion.
Combination Product: Infasurf Aero™
Low flow respiratory air alone through the InfasurfAero™ Nebulizer until completion.
Combination Product: Infasurf Aero™
A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.
CPAP failure and or death
CPAP failure is defined as a respiratory severity score (RSS) (MAP x FiO2) \>2.5 on two consecutive assessments at least 30 minutes apart, or an RSS \> 2.4 and one or more of the following: (i) Silverman-Andersen respiratory severity score (https://www.thecalculator.co/health/Silverman-Score-Calculator-1125.html) of ≥ 5 despite respiratory support. (ii) Severe apnea (2 or more episodes per hour, or 1 or more episodes requiring manual positive pressure ventilation). (iii) Respiratory acidosis (pCO2 \> 65 with a pH \< 7.2 on blood gas). RSS will be the primary indicator of CPAP failure. However with the addition of the Silverman-Anderson scores, severe apnea and respiratory acidosis, CPAP failure may occur earlier than solely defined by RSS score.
Time frame: Within 1st week of age
Chronic lung disease and or death
Chronic lung disease is defined as altitude adjusted oxygen requirement at 36 weeks post menstrual age.
Time frame: 36 weeks post menstrual age (PMA).
Incidence of MV
Incidence of Mechanical Ventilation
Time frame: 36 weeks PMA
Duration of MV
length of time of Mechanical Ventilation
Time frame: 36 weeks PMA
Incidence of intubation
Any occurrence of tracheal intubation
Time frame: 36 weeks PMA
Incidence of invasive surfactant replacement therapy
any occurrence of liquid surfactant administration via and endotracheal tube
Time frame: 72 hours post birth
Duration of non-invasive support
Length of time of respiratory support other than Intubation
Time frame: 36 weeks PMA
Duration of supplemental oxygen
Length of time any oxygen is administered.
Time frame: 36 weeks PMA
Adverse events during surfactant administration.
Incidence of bradycardia and desaturation during surfactant administration.
Time frame: Birth to 72 hours of age.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jan 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ONY